Dynasil Corporation of America (DYSL) 10-Q 13 May 15 2015 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Mar. 31, 2015	6-May-15
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Entity Registrant Name	DYNASIL CORP OF AMERICA
Entity Central Index Key	30831
Current Fiscal Year End Date	-21
Entity Filer Category	Smaller Reporting Company
Trading Symbol	DYSL
Entity Common Stock, Shares Outstanding		16,460,960

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Sep. 30, 2014
Current Assets
Cash and cash equivalents	$3,201,000	$3,842,000
Accounts receivable, net of allowances of $134,000 and $299,000 at March 31, 2015 and September 30, 2014, respectively	3,334,000	3,240,000
Costs in excess of billings and unbilled receivables	1,237,000	1,235,000
Inventories, net of reserves	3,010,000	2,954,000
Prepaid expenses and other current assets	1,047,000	861,000
Total current assets	11,829,000	12,132,000
Property, Plant and Equipment, net	6,369,000	6,518,000
Other Assets
Intangibles, net	1,235,000	1,383,000
Goodwill	6,096,000	6,247,000
Deferred financing costs, net	32,000	39,000
Security deposits	58,000	58,000
Total other assets	7,421,000	7,727,000
Total Assets	25,619,000	26,377,000
Current Liabilities
Current portion of long-term debt	3,412,000	2,329,000
Capital lease obligations, current	132,000	134,000
Convertible notes	1,468,000	1,433,000
Accounts payable	1,746,000	1,602,000
Deferred revenue	31,000	103,000
Accrued expenses and other liabilities	2,321,000	2,503,000
Total current liabilities	9,110,000	8,104,000
Long-term Liabilities
Long-term debt, net of current portion	2,461,000	3,282,000
Capital lease obligations, net of current portion	62,000	95,000
Pension liability	0	318,000
Deferred tax liability	238,000	264,000
Other long-term liabilities	43,000	0
Total long-term liabilities	2,804,000	3,959,000
Stockholders' Equity
Common Stock, $0.0005 par value, 40,000,000 shares authorized, 17,234,699 and 17,140,182 shares issued, 16,424,539 and and 16,330,022 shares outstanding at March 31, 2015 and September 30, 2014, respectively.	9,000	9,000
Additional paid in capital	19,341,000	19,195,000
Accumulated other comprehensive income	27,000	98,000
Accumulated deficit	-4,565,000	-3,933,000
Less 810,160 shares of treasury stock - at cost	-986,000	-986,000
Total Dynasil stockholders' equity	13,826,000	14,383,000
Noncontrolling interest	-121,000	-69,000
Total stockholders' equity	13,705,000	14,314,000
Total Liabilities and Stockholders' Equity	$25,619,000	$26,377,000

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2015	Sep. 30, 2014
Allowance for doubtful accounts (in dollars)	$134,000	$299,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	17,234,699	17,140,182
Common stock, shares outstanding	16,424,539	16,330,022
Treasury stock, shares	810,160	810,160

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Net revenue	$9,895,000	$10,407,000	$19,506,000	$21,118,000
Cost of revenue	6,135,000	6,048,000	12,154,000	12,309,000
Gross profit	3,760,000	4,359,000	7,352,000	8,809,000
Operating expenses:
Sales and marketing	309,000	313,000	674,000	710,000
Research and development	416,000	378,000	790,000	725,000
General and administrative	3,021,000	3,201,000	6,488,000	6,480,000
Gain on sale of assets	0	0	-185,000	-1,187,000
Total operating expenses	3,746,000	3,892,000	7,767,000	6,728,000
Income (loss) from operations	14,000	467,000	-415,000	2,081,000
Interest expense, net	123,000	209,000	248,000	422,000
Income (loss) before taxes	-109,000	258,000	-663,000	1,659,000
Income tax (credit)	18,000	5,000	21,000	-40,000
Net income (loss)	-127,000	253,000	-684,000	1,699,000
Less: Net loss attributable to noncontrolling interest	-28,000	-19,000	-52,000	-30,000
Net income (loss) attributable to common stockholders	-99,000	272,000	-632,000	1,729,000
Net income (loss)	-127,000	253,000	-684,000	1,699,000
Other comprehensive income (loss):
(Increase) decrease in pension liability	0	0	318,000	0
Foreign currency translation	-195,000	37,000	-389,000	73,000
Total comprehensive income (loss)	($322,000)	$290,000	($755,000)	$1,772,000
Basic net income (loss) per common share (in dollars per share)	($0.01)	$0.02	($0.04)	$0.11
Diluted net income (loss) per common share (in dollars per share)	($0.01)	$0.02	($0.04)	$0.11
Weighted average shares outstanding
Basic (in shares)	16,365,688	15,102,023	16,333,295	15,061,890
Diluted (in shares)	16,365,688	15,285,232	16,333,295	15,216,915

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Balance at Sep. 30, 2014	$14,314,000	$9,000	$19,195,000	$98,000	($3,933,000)	($986,000)	($69,000)
Balance (in shares) at Sep. 30, 2014		17,140,182				810,160
Issuance of shares of common stock under employee stock purchase plan	6,000	0	6,000	0	0	0	0
Issuance of shares of common stock under employee stock purchase plan (in shares)		5,387				0
Stock-based compensation costs	157,000	0	157,000	0	0	0	0
Stock-based compensation costs (in shares)		98,772				0
Adjustment for escrow settlement	-17,000	0	-17,000	0	0	0	0
Adjustment for escrow settlement (in shares)		-9,642
Settlement of pension obligation, net of tax	318,000	0	0	318,000	0	0	0
Foreign currency translation adjustment	-389,000	0	0	-389,000	0	0	0
Net income (loss)	-684,000	0	0	0	-632,000	0	-52,000
Balance at Mar. 31, 2015	$13,705,000	$9,000	$19,341,000	$27,000	($4,565,000)	($986,000)	($121,000)
Balance (in shares) at Mar. 31, 2015		17,234,699				810,160

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income (loss)	($684,000)	$1,699,000
Adjustments to reconcile net income (loss) to net cash:
Stock compensation expense	157,000	239,000
Foreign exchange loss (gain)	-95,000	14,000
Gain on sale of assets	-185,000	-1,187,000
Depreciation and amortization	586,000	535,000
Pension expense	318,000	0
Other	20,000	74,000
Other changes in assets and libilities:
Accounts receivable, net	-40,000	448,000
Inventories	-14,000	-532,000
Costs in excess of billings and unbilled receivables	-2,000	-380,000
Prepaid expenses and other assets	-150,000	-99,000
Accounts payable	108,000	231,000
Accrued expenses and other liabilities	-529,000	883,000
Deferred revenue	-72,000	-320,000
Net cash from operating activities	-582,000	1,605,000
Cash flows from investing activities:
Proceeds from sale of assets	244,000	4,357,000
Purchases of property, plant and equipment	-456,000	-539,000
Net cash from investing activities	-212,000	3,818,000
Cash flows from financing activities:
Proceeds from issuance of common stock	6,000	7,000
Net proceeds from issuance of convertible notes	0	383,000
Principal payments on capital leases	-73,000	-64,000
Proceeds from short and long-term debt	300,000	141,000
Payments on long-term debt	-38,000	-4,856,000
Net cash from financing activities	195,000	-4,389,000
Effect of exchange rates on cash and cash equivalents	-42,000	-5,000
Net change in cash and cash equivalents	-641,000	1,029,000
Cash and cash equivalents, beginning	3,842,000	2,437,000
Cash and cash equivalents, ending	3,201,000	3,466,000
Non cash activities:
Assets purchased under capital leases	73,000	0
Tax payments (refunds)	($13,000)	$0

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Basis of Presentation and Significant Accounting Policies [Text Block]	Note 1 - Basis of Presentation
	The accompanying consolidated balance sheet as of March 31, 2015, the consolidated statements of operations and comprehensive income (loss) for the three and six months ended March 31, 2015 and 2014, changes in stockholders’ equity for the six months ended March 31, 2015 and cash flows for the six months ended March 31, 2015 and 2014 of Dynasil Corporation of America and subsidiaries (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year.
	The preparation of our unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company's annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's September 30, 2014 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission.
	The Company considers events or transactions that have occurred after the unaudited consolidated balance sheet date of March 31, 2015, but prior to the filing of the unaudited consolidated financial statements with the SEC on this Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Acquisitions_and_Divestitures

Acquisitions and Divestitures	6 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Note 2 – Acquisitions and Divestitures
	On June 26, 2014, the Company and its wholly owned subsidiary, Evaporated Metal Films Corp. (“EMF”) acquired substantially all the assets of DichroTec Thin Films, LLC (“DichroTec”), a manufacturer of optical thin film coatings. The total purchase price paid of $1.7 million, consisting of approximately $0.5 million in cash and 690,000 shares of Dynasil common stock, was allocated primarily to machinery and equipment. DichroTec reported unaudited revenues of approximately $1.9 million for the twelve months ended December 31, 2013.
	The Company sold its Lead Paint detector and Gamma Medical Probe businesses on November 7, 2013 and December 23, 2013, respectively. These businesses constituted substantially all the Company’s Instruments segment but did not qualify to be reported as discontinued operations. The businesses were sold for an aggregate of approximately $4.7 million, including the assumption of certain liabilities of the Company and a possible contingent payment and resulted in a gain of $1.2 million which is included in Income from Operations in the six months ended March 31, 2014. The Company used $3.9 million of the proceeds from the two sale transactions to reduce its indebtedness to Santander Bank, N.A., its former lender.
	In the three months ended December 31, 2014, the Company recorded a gain of $0.2 million in connection with the sale of a product line in its Optics segment.

Xcede_Technologies_Inc_Joint_V

Xcede Technologies, Inc. Joint Venture	6 Months Ended
	Mar. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	Note 3 – Xcede Technologies, Inc. Joint Venture
	In October, 2013, the Company formed Xcede Technologies, Inc. (“Xcede”), a joint venture with Mayo Clinic, in order to spin out and separately fund the development of its tissue sealant technology, which formerly comprised the majority of its biomedical segment. Xcede has raised approximately $1.4 million in external funding in the form of Convertible Notes (the “Notes”) from outside investors including certain officers and directors of the Company. The Notes accrue interest at 5% and are due upon the demand of the holders of a majority of the aggregate outstanding principal amount of the Notes, after June 30, 2015.
	Upon the closing of a capital stock financing raising at least $3.0 million, inclusive of the Notes and interest, the outstanding principal amount of the Notes plus all accrued interest will be converted into shares of the same capital stock sold in the financing at a 20% discount to the price per share of that capital stock. Alternatively, at any time prior to a capital stock financing the Note holders can convert, at their option, the principal amount of the Notes plus accrued interest into common stock based on a $5 million valuation.
	Xcede is 90% owned by Dynasil Biomedical and, as a result, is included in the Company’s consolidated balance sheet, results of operations and cash flows. In 2015, Xcede has recognized $14,000 of stock compensation expense related to options to purchase Xcede’s stock granted to its employees and directors.
	The Company expects Xcede to require significant additional funding prior to commencing human trials.

Inventories

Inventories	6 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 - Inventories
	Inventories, net of reserves, consists of the following:
		March 31,		September 30,
		2015		2014
	Raw Materials	$	1,875,000	$	1,805,000
	Work-in-Process		821,000		858,000
	Finished Goods		314,000		291,000
		$	3,010,000	$	2,954,000

Intangible_Assets

Intangible Assets	6 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 5 – Intangible Assets
	Intangible assets at March 31, 2015 and September 30, 2014 consist of the following:
		Useful		Gross			Accumulated
	March 31, 2015	Life (years)		Amount			Amortization			Net
	Acquired Customer Base	5 to 15		$	808,000		$	419,000		$	389,000
	Know How	15			512,000			230,000			282,000
	Trade Names	Indefinite			310,000			-			310,000
	Patents	20			164,000			-			164,000
	Biomedical Technologies	5			260,000			170,000			90,000
				$	2,054,000		$	819,000		$	1,235,000
		Useful		Gross			Accumulated
	September 30, 2014	Life (years)		Amount			Amortization			Net
	Acquired Customer Base	5 to 15		$	877,000		$	409,000		$	468,000
	Know How	15			512,000			213,000			299,000
	Trade Names	Indefinite			339,000			-			339,000
	Patents	20			159,000			-			159,000
	Biomedical Technologies	5			260,000			142,000			118,000
				$	2,147,000		$	764,000		$	1,383,000
	Amortization expense for the three months ended March 31, 2015 and 2014 was $42,000 and $44,000, respectively. Amortization expense for the six months ended March 31, 2015 and 2014 was $85,000 and $89,000, respectively.
	Estimated amortization expense for each of the next five fiscal years is as follows:
		2015 (6 months)			2016			2017			2018		2019		Thereafter		Total
	Acquired Customer Base	$	40,000		$	80,000		$	80,000		$	80,000	$	80,000	$	29,000	$	389,000
	Know How		17,000			34,000			34,000			34,000		34,000		129,000		282,000
	Patents		8,000			8,000			8,000			8,000		8,000		124,000		164,000
	Biomedical Technologies		30,000			60,000			-			-		-		-		90,000
		$	95,000		$	182,000		$	122,000		$	122,000	$	122,000	$	282,000	$	925,000

Goodwill

Goodwill	6 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure [Text Block]	Note 6 – Goodwill
	Goodwill is subject to an annual impairment test. The Company considers many factors which may indicate the requirement to perform additional, interim impairment tests. These include:
		⋅	A significant adverse long term outlook for any of its industries;
		⋅	An adverse finding or rejection from a regulatory body involved in new product regulatory approvals;
		⋅	Failure of an anticipated commercialization of a product or product line;
		⋅	Unanticipated competition or the introduction of a disruptive technology;
		⋅	The testing for recoverability under the Impairment or Disposal of Long-Lived Assets Subsections of Subtopic 360-10 of a significant asset group within a reporting unit;
		⋅	A loss of key personnel; and
		⋅	An expectation that a reporting unit carrying goodwill, or a significant portion of a reporting unit, will be sold or otherwise disposed of.
	There were no changes, aside from foreign exchange rate fluctuations, in the carrying value of goodwill during the three and six months ended March 31, 2015.

Earnings_Loss_Per_Common_Share

Earnings (Loss) Per Common Share	6 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 7 – Earnings (Loss) Per Common Share
	Basic earnings (loss) per common share is computed by dividing the net income applicable or loss attributable to common shares by the weighted average number of common shares. Diluted earnings per common share adjusts basic earnings per share for the effects of common stock options, common stock warrants, convertible preferred stock and other potential dilutive common shares outstanding during the periods.
	For purposes of computing diluted earnings per share for the three and six months ended March 31, 2015 and 2014, no common stock options were included in the calculation of dilutive shares as all of the 58,212 and 630,532 common stock options outstanding, respectively, had exercise prices above the current quarterly average market price per share and their inclusion would be anti-dilutive. Additionally, for the three and six months ended March 31, 2015, no common share equivalents related to stock options or unvested restricted stock were included in the calculation of dilutive shares, since there was a loss from continuing operations and the inclusion of common share equivalents would be anti-dilutive.
	The computation of the weighted shares outstanding for the three months ended March 31, 2015 and 2014 is as follows:
		March 31, 2015		March 31, 2014
	Weighted average shares outstanding
	Basic		16,365,688		15,102,023
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		-		183,209
	Dilutive Average Shares Outstanding		16,365,688		15,285,232
	The computation of the weighted shares outstanding for the six months ended March 31, 2015 and 2014 is as follows:
		March 31, 2015		March 31, 2014
	Weighted average shares outstanding
	Basic		16,333,295		15,061,890
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		-		155,025
	Dilutive Average Shares Outstanding		16,333,295		15,216,915

Stock_Based_Compensation

Stock Based Compensation	6 Months Ended
	Mar. 31, 2015
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 8 - Stock Based Compensation
	The fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model. The weighted average assumptions for the stock option grant during the six months ended March 31, 2015 used in the Black-Scholes option pricing model were as follows:
		Six Months Ended
		March 31, 2015
	Expected term in years		3 years
	Risk-free interest rate		0.77	%
	Expected volatility		89.46	%
	Expected dividend yield		0	%
	The expected volatility was determined with reference to the historical volatility of the Company's stock. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of options granted represents the period of time that the options granted are expected to be outstanding. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate in effect at the time of grant. The dividend yield is expected to be 0.00% because historically the Company has not paid dividends on common stock.
	During the three months ended March 31, 2015, 36,232 stock options were granted at the exercise price of $1.82 per share. These options were granted as a component of Directors’ Compensation for the twelve months ending January 31, 2016 and were fully exercisable when granted, and expire three years from the grant date. The stock-based compensation expense of $25,000 will be recognized over the requisite service period.
	A summary of stock option activity for the six months ended March 31, 2015 is presented below:
		Options			Weighted Average		Weighted Average
		Outstanding			Exercise Price per		Remain Contractual
					Share		Term (in Years)
	Balance at September 30, 2014		430,532		$	3.33		0.31
	Granted		36,232			1.82		2.84
	Exercised		-			-
	Cancelled		-408,552			3.99
	Balance at March 31, 2015		58,212		$	2.28		2.47
	Outstanding and exercisable at March 31, 2015		58,212		$	2.28		2.47
	A summary of restricted stock activity for the six months ended March 31, 2015 is presented below:
	Restricted Stock Activity for the Six	Shares			Weighted-Average
	Months ended March 31, 2015				Grant-Date Fair Value
	Nonvested at September 30, 2014		54,000		$	1.04
	Granted		-		$	-
	Vested		-27,000		$	1.04
	Cancelled		-		$	-
	Nonvested at March 31, 2015		27,000		$	1.04
	Stock Compensation Expense for the three and six months ended March 31, 2015 and 2014 is as follows:
		Three Months Ended			Three Months Ended
	Stock Compensation Expense	March 31, 2015			March 31, 2014
	Stock Grants	$	80,000		$	51,000
	Restricted Stock Grants		7,000			68,000
	Option Grants		4,000			-
	Employee Stock Purchase Plan		1,000			1,000
	Total	$	92,000		$	120,000
		Six Months Ended			Six Months Ended
	Stock Compensation Expense	March 31, 2015			March 31, 2014
	Stock Grants	$	137,000		$	101,000
	Restricted Stock Grants		14,000			137,000
	Option Grants		4,000			-
	Employee Stock Purchase Plan		2,000			1,000
	Total	$	157,000		$	239,000
	At March 31, 2015 there was approximately $60,000 in unrecognized stock compensation cost, which is expected to be recognized over a weighted average period of three months.

Segment_Customer_and_Geographi

Segment, Customer and Geographical Reporting	6 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 9 – Segment, Customer and Geographical Reporting
	Segment Financial Information
	Dynasil’s business is comprised of four segments: contract research (“Contract Research”), optics (“Optics”), instruments (“Instruments”) and biomedical (“Biomedical”). Substantially all the operating assets of the Instruments segment were sold in the three months ended December 31, 2013.
	Within these segments, there is a segregation of reportable units based upon the organizational structure used to evaluate performance and make decisions on resource allocation, as well as availability and materiality of separate financial results consistent with that structure. The Contract Research segment is one of the largest small business participants in U.S. government-funded research. The Optics segment manufactures optical materials, components and coatings. The Biomedical segment, through Xcede Technologies, Inc., a majority owned, joint venture, is focused on developing a tissue sealant technology for a wide spectrum of applications though no assurance can be given that this technology will become successfully commercialized.
	The Company’s segment information for the three months ended March 31, 2015 and 2014 is summarized below:
	Results of Operations for the Three Months Ended March 31,
	2015
		Contract				Optics				Instruments			Biomedical			Total
		Research
	Revenue	$	4,675,000			$	5,220,000			$	-		$	-		$	9,895,000
	Gross Profit		1,952,000				1,808,000				-			-			3,760,000
	GM %		41.8	%			34.6	%			-			-			38	%
	SG&A		1,896,000				1,580,000				-			270,000			3,746,000
	Gain on sale of assets		-				-				-			-			-
	Operating Income (Loss)		56,000				228,000				-			-270,000			14,000
	Depreciation and Amortization		74,000				204,000				-			15,000			293,000
	Capital expenditures		4,000				152,000				-			56,000			212,000
	Intangibles, Net		282,000				699,000				-			254,000			1,235,000
	Goodwill		4,939,000				1,157,000				-			-			6,096,000
	Total Assets	$	8,887,000			$	15,800,000			$	238,000		$	694,000		$	25,619,000
	Results of Operations for the Three Months Ended March 31,
	2014
		Contract				Optics				Instruments			Biomedical				Total
		Research
	Revenue	$	5,614,000			$	4,789,000			$	-		$	4,000			$	10,407,000
	Gross Profit		2,442,000				1,919,000				-6,000			4,000				4,359,000
	GM %		43.5	%			40.1	%			-			100	%			41.9	%
	SG&A		2,200,000				1,397,000				70,000			225,000				3,892,000
	Gain on sale of assets		-				-				-			-				-
	Operating Income (Loss)		242,000				522,000				-76,000			-221,000				467,000
	Depreciation and Amortization		70,000				183,000				-			15,000				268,000
	Capital expenditures		12,000				397,000				-			-				409,000
	Intangibles, Net		316,000				858,000				-			148,000				1,322,000
	Goodwill		4,939,000				1,333,000				-			-				6,272,000
	Total Assets	$	10,230,000			$	13,816,000			$	455,000		$	332,000			$	24,833,000
	The Company’s segment information for the six months ended March 31, 2015 and 2014 is summarized below:
	Results of Operations for the Six Months Ended March 31,
	2015
		Contract				Optics				Instruments			Biomedical			Total
		Research
	Revenue	$	9,338,000			$	10,168,000			$	-		$	-		$	19,506,000
	Gross Profit		4,050,000				3,302,000				-			-			7,352,000
	GM %		43.4	%			32.5	%			-			-			37.7	%
	SG&A		3,778,000				3,670,000				-			504,000			7,952,000
	Gain on sale of assets		-				-185,000				-			-			-185,000
	Operating Income (Loss)		272,000				-183,000				-			-504,000			-415,000
	Depreciation and Amortization		148,000				408,000				-			30,000			586,000
	Capital expenditures		4,000				396,000				-			56,000			456,000
	Intangibles, Net		282,000				699,000				-			254,000			1,235,000
	Goodwill		4,939,000				1,157,000				-			-			6,096,000
	Total Assets	$	8,887,000			$	15,800,000			$	238,000		$	694,000		$	25,619,000
	Results of Operations for the Six Months Ended March 31,
	2014
		Contract				Optics				Instruments				Biomedical				Total
		Research
	Revenue	$	11,454,000			$	8,887,000			$	773,000			$	4,000			$	21,118,000
	Gross Profit		4,971,000				3,517,000				317,000				4,000				8,809,000
	GM %		43.4	%			39.6	%			41	%			100	%			41.7	%
	SG&A		4,381,000				2,596,000				539,000				399,000				7,915,000
	Gain on sale of assets		-				-				-1,187,000				-				-1,187,000
	Operating Income (Loss)		590,000				921,000				965,000				-395,000				2,081,000
	Depreciation and Amortization		139,000				362,000				2,000				32,000				535,000
	Capital expenditures		12,000				527,000				-				-				539,000
	Intangibles, Net		316,000				858,000				-				148,000				1,322,000
Goodwill		4,939,000				1,333,000				-				-				6,272,000
Total Assets	$	10,230,000			$	13,816,000			$	455,000			$	332,000			$	24,833,000
Customer Financial Information
For the three and six months ended March 31, 2015, four customers of the Contract Research segment, all various agencies of the U.S. Government, each represented more than 10% of the total segment revenue. For the three and six months ended March 31, 2014, three customers, all various agencies of the U.S. Government, each represented more than 10% of the total segment revenue. For both the three months ended March 31, 2015 and 2014, these customers made up 69% of Contract Research revenue. For the six months ended March 31, 2015 and 2014, these customers made up 70% and 67%, respectively, of Contract Research revenue.
For the three and six months ended March 31, 2015 and 2014, there was no customer in the Optics segment whose revenue represented more than 10% of the total segment revenue.
Geographic Financial Information
Revenue by geographic location in total and as a percentage of total revenue, for the three months ended March 31, 2015 and 2014 are as follows:
	Three Months Ended						Three Months Ended
	March 31, 2015						March 31, 2014
Geographic Location	Revenue			% of Total			Revenue			% of Total
United States	$	7,982,000		81	%		$	8,622,000		83	%
Europe		1,124,000		11	%			845,000		8	%
Other		789,000		8	%			940,000		9	%
	$	9,895,000		100	%		$	10,407,000		100	%
Revenue by geographic location in total and as a percentage of total revenue, for the six months ended March 31, 2015 and 2014 are as follows:
	Six Months Ended						Six Months Ended
	March 31, 2015						March 31, 2014
Geographic Location	Revenue			% of Total			Revenue			% of Total
United States	$	15,664,000		80	%		$	17,529,000		83	%
Europe		2,008,000		10	%			1,675,000		8	%
Other		1,834,000		10	%			1,914,000		9	%
	$	19,506,000		100	%		$	21,118,000		100	%

Income_Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 10 - Income Taxes
	Dynasil Corporation of America and its wholly-owned U.S. subsidiaries file a consolidated federal income tax return and various state returns. The Company’s U.K. subsidiary files tax returns in the U.K.
	The Company uses the asset and liability approach to account for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carry forwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates, and tax laws, in the respective tax jurisdiction then in effect.
	In assessing the ability to realize the net deferred tax assets, management considers various factors including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and projections of future taxable income, to determine whether it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Based upon the Company’s recent losses and uncertainty of future profits, the Company has determined that the uncertainty regarding the realization of these assets is sufficient to warrant the need for a full valuation allowance against its U.S. net deferred tax assets.
	The Company applies the authoritative provisions related to accounting for uncertainty in income taxes. As required by these provisions, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being reached upon ultimate settlement with the relevant tax authority. As of March 31, 2015 and September 30, 2014, the Company has no unrecorded liabilities for uncertain tax positions. Interest and penalty charges, if any, related to uncertain tax positions would be classified as income tax expense in the accompanying consolidated statement of operations. As of March 31, 2015 and September 30, 2014, the Company had no accrued interest or penalties related to uncertain tax positions. The Company currently has no federal or state tax examinations in progress.
	The effective tax rates were (15.84%) and (3.29%) for the three and six months ended March 31, 2015, respectively, and 1.8% and (2.4%) for the three and six months ended March 31, 2014, respectively. The rates differ from the U.S. federal statutory income tax rate of 34% primarily due to a full valuation allowance against the Company’s U.S. deferred tax asset.
	The Company files its tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The Company’s tax filings for federal and state jurisdictions for the tax years beginning with 2010 are still subject to examination.

Settlement_of_Pension_Liabilit

Settlement of Pension Liability	6 Months Ended
	Mar. 31, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule Of Defined Benefit Plans Disclosure [Text Block]	Note 11 – Settlement of Pension Liability
	On December 1, 2014, the Company terminated and settled its pension liability with each of the remaining participants in the EMF Defined Benefit Plan (the “Plan”). The Plan had been frozen since 2006. The total benefit payments made upon termination were $688,000 and the actual plan assets at the date of termination were $332,000. The Company funded and expensed the difference upon settlement of the Plan.

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories, net of reserves, consists of the following:
		March 31,		September 30,
		2015		2014
	Raw Materials	$	1,875,000	$	1,805,000
	Work-in-Process		821,000		858,000
	Finished Goods		314,000		291,000
		$	3,010,000	$	2,954,000

Intangible_Assets_Tables

Intangible Assets (Tables)	6 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Intangible assets at March 31, 2015 and September 30, 2014 consist of the following:
		Useful		Gross			Accumulated
	March 31, 2015	Life (years)		Amount			Amortization			Net
	Acquired Customer Base	5 to 15		$	808,000		$	419,000		$	389,000
	Know How	15			512,000			230,000			282,000
	Trade Names	Indefinite			310,000			-			310,000
	Patents	20			164,000			-			164,000
	Biomedical Technologies	5			260,000			170,000			90,000
				$	2,054,000		$	819,000		$	1,235,000
		Useful		Gross			Accumulated
	September 30, 2014	Life (years)		Amount			Amortization			Net
	Acquired Customer Base	5 to 15		$	877,000		$	409,000		$	468,000
	Know How	15			512,000			213,000			299,000
	Trade Names	Indefinite			339,000			-			339,000
	Patents	20			159,000			-			159,000
	Biomedical Technologies	5			260,000			142,000			118,000
				$	2,147,000		$	764,000		$	1,383,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense for each of the next five fiscal years is as follows:
		2015 (6 months)			2016			2017			2018		2019		Thereafter		Total
	Acquired Customer Base	$	40,000		$	80,000		$	80,000		$	80,000	$	80,000	$	29,000	$	389,000
	Know How		17,000			34,000			34,000			34,000		34,000		129,000		282,000
	Patents		8,000			8,000			8,000			8,000		8,000		124,000		164,000
	Biomedical Technologies		30,000			60,000			-			-		-		-		90,000
		$	95,000		$	182,000		$	122,000		$	122,000	$	122,000	$	282,000	$	925,000

Earnings_Loss_Per_Common_Share1

Earnings (Loss) Per Common Share (Tables)	6 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The computation of the weighted shares outstanding for the three months ended March 31, 2015 and 2014 is as follows:
		March 31, 2015		March 31, 2014
	Weighted average shares outstanding
	Basic		16,365,688		15,102,023
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		-		183,209
	Dilutive Average Shares Outstanding		16,365,688		15,285,232
	The computation of the weighted shares outstanding for the six months ended March 31, 2015 and 2014 is as follows:
		March 31, 2015		March 31, 2014
	Weighted average shares outstanding
	Basic		16,333,295		15,061,890
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		-		155,025
	Dilutive Average Shares Outstanding		16,333,295		15,216,915

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	6 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The weighted average assumptions for the stock option grant during the six months ended March 31, 2015 used in the Black-Scholes option pricing model were as follows:
		Six Months Ended
		March 31, 2015
	Expected term in years		3 years
	Risk-free interest rate		0.77	%
	Expected volatility		89.46	%
	Expected dividend yield		0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of stock option activity for the six months ended March 31, 2015 is presented below:
		Options			Weighted Average		Weighted Average
		Outstanding			Exercise Price per		Remain Contractual
					Share		Term (in Years)
	Balance at September 30, 2014		430,532		$	3.33		0.31
	Granted		36,232			1.82		2.84
	Exercised		-			-
	Cancelled		-408,552			3.99
	Balance at March 31, 2015		58,212		$	2.28		2.47
	Outstanding and exercisable at March 31, 2015		58,212		$	2.28		2.47
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	summary of restricted stock activity for the six months ended March 31, 2015 is presented below:
	Restricted Stock Activity for the Six	Shares			Weighted-Average
	Months ended March 31, 2015				Grant-Date Fair Value
	Nonvested at September 30, 2014		54,000		$	1.04
	Granted		-		$	-
	Vested		-27,000		$	1.04
	Cancelled		-		$	-
	Nonvested at March 31, 2015		27,000		$	1.04
Schedule Of Stock Compensation Expense [Table Text Block]	Stock Compensation Expense for the three and six months ended March 31, 2015 and 2014 is as follows:
		Three Months Ended			Three Months Ended
	Stock Compensation Expense	March 31, 2015			March 31, 2014
	Stock Grants	$	80,000		$	51,000
	Restricted Stock Grants		7,000			68,000
	Option Grants		4,000			-
	Employee Stock Purchase Plan		1,000			1,000
	Total	$	92,000		$	120,000
		Six Months Ended			Six Months Ended
	Stock Compensation Expense	March 31, 2015			March 31, 2014
	Stock Grants	$	137,000		$	101,000
	Restricted Stock Grants		14,000			137,000
	Option Grants		4,000			-
	Employee Stock Purchase Plan		2,000			1,000
	Total	$	157,000		$	239,000

Segment_Customer_and_Geographi1

Segment, Customer and Geographical Reporting (Tables)	6 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The Company’s segment information for the three months ended March 31, 2015 and 2014 is summarized below:
	Results of Operations for the Three Months Ended March 31,
	2015
		Contract				Optics				Instruments			Biomedical			Total
		Research
	Revenue	$	4,675,000			$	5,220,000			$	-		$	-		$	9,895,000
	Gross Profit		1,952,000				1,808,000				-			-			3,760,000
	GM %		41.8	%			34.6	%			-			-			38	%
	SG&A		1,896,000				1,580,000				-			270,000			3,746,000
	Gain on sale of assets		-				-				-			-			-
	Operating Income (Loss)		56,000				228,000				-			-270,000			14,000
	Depreciation and Amortization		74,000				204,000				-			15,000			293,000
	Capital expenditures		4,000				152,000				-			56,000			212,000
	Intangibles, Net		282,000				699,000				-			254,000			1,235,000
	Goodwill		4,939,000				1,157,000				-			-			6,096,000
	Total Assets	$	8,887,000			$	15,800,000			$	238,000		$	694,000		$	25,619,000
	Results of Operations for the Three Months Ended March 31,
	2014
		Contract				Optics				Instruments			Biomedical				Total
		Research
	Revenue	$	5,614,000			$	4,789,000			$	-		$	4,000			$	10,407,000
	Gross Profit		2,442,000				1,919,000				-6,000			4,000				4,359,000
	GM %		43.5	%			40.1	%			-			100	%			41.9	%
	SG&A		2,200,000				1,397,000				70,000			225,000				3,892,000
	Gain on sale of assets		-				-				-			-				-
	Operating Income (Loss)		242,000				522,000				-76,000			-221,000				467,000
	Depreciation and Amortization		70,000				183,000				-			15,000				268,000
	Capital expenditures		12,000				397,000				-			-				409,000
	Intangibles, Net		316,000				858,000				-			148,000				1,322,000
	Goodwill		4,939,000				1,333,000				-			-				6,272,000
	Total Assets	$	10,230,000			$	13,816,000			$	455,000		$	332,000			$	24,833,000
	The Company’s segment information for the six months ended March 31, 2015 and 2014 is summarized below:
	Results of Operations for the Six Months Ended March 31,
	2015
		Contract				Optics				Instruments			Biomedical			Total
		Research
	Revenue	$	9,338,000			$	10,168,000			$	-		$	-		$	19,506,000
	Gross Profit		4,050,000				3,302,000				-			-			7,352,000
	GM %		43.4	%			32.5	%			-			-			37.7	%
	SG&A		3,778,000				3,670,000				-			504,000			7,952,000
	Gain on sale of assets		-				-185,000				-			-			-185,000
	Operating Income (Loss)		272,000				-183,000				-			-504,000			-415,000
	Depreciation and Amortization		148,000				408,000				-			30,000			586,000
	Capital expenditures		4,000				396,000				-			56,000			456,000
	Intangibles, Net		282,000				699,000				-			254,000			1,235,000
	Goodwill		4,939,000				1,157,000				-			-			6,096,000
	Total Assets	$	8,887,000			$	15,800,000			$	238,000		$	694,000		$	25,619,000
	Results of Operations for the Six Months Ended March 31,
	2014
		Contract				Optics				Instruments				Biomedical				Total
		Research
	Revenue	$	11,454,000			$	8,887,000			$	773,000			$	4,000			$	21,118,000
	Gross Profit		4,971,000				3,517,000				317,000				4,000				8,809,000
	GM %		43.4	%			39.6	%			41	%			100	%			41.7	%
	SG&A		4,381,000				2,596,000				539,000				399,000				7,915,000
	Gain on sale of assets		-				-				-1,187,000				-				-1,187,000
	Operating Income (Loss)		590,000				921,000				965,000				-395,000				2,081,000
	Depreciation and Amortization		139,000				362,000				2,000				32,000				535,000
	Capital expenditures		12,000				527,000				-				-				539,000
	Intangibles, Net		316,000				858,000				-				148,000				1,322,000
	Goodwill		4,939,000				1,333,000				-				-				6,272,000
	Total Assets	$	10,230,000			$	13,816,000			$	455,000			$	332,000			$	24,833,000
Schedule Of Segment Revenue By Geographical Location [Table Text Block]	Revenue by geographic location in total and as a percentage of total revenue, for the three months ended March 31, 2015 and 2014 are as follows:
		Three Months Ended						Three Months Ended
		March 31, 2015						March 31, 2014
	Geographic Location	Revenue			% of Total			Revenue			% of Total
	United States	$	7,982,000		81	%		$	8,622,000		83	%
	Europe		1,124,000		11	%			845,000		8	%
	Other		789,000		8	%			940,000		9	%
		$	9,895,000		100	%		$	10,407,000		100	%
	Revenue by geographic location in total and as a percentage of total revenue, for the six months ended March 31, 2015 and 2014 are as follows:
		Six Months Ended						Six Months Ended
		March 31, 2015						March 31, 2014
	Geographic Location	Revenue			% of Total			Revenue			% of Total
	United States	$	15,664,000		80	%		$	17,529,000		83	%
	Europe		2,008,000		10	%			1,675,000		8	%
	Other		1,834,000		10	%			1,914,000		9	%
		$	19,506,000		100	%		$	21,118,000		100	%

Acquisitions_and_Divestitures_

Acquisitions and Divestitures (Details Textual) (USD $)	3 Months Ended			6 Months Ended		1 Months Ended	12 Months Ended	1 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Jun. 26, 2014	Dec. 31, 2013	Dec. 23, 2013
Business Acquisition [Line Items]
Revenue, Net, Total	$9,895,000		$10,407,000	$19,506,000	$21,118,000
Proceeds from (Repayments of) Debt					1,200,000
Gain (Loss) on Disposition of Business		200,000
Dichrotec [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross						500,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						690,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned						1,700,000
Revenue, Net, Total							1,900,000
Dilon [Member]
Business Acquisition [Line Items]
Proceeds from Sales of Business, Affiliate and Productive Assets								4,700,000
Proceeds from (Repayments of) Debt				$3,900,000

Xcede_Technologies_Inc_Joint_V1

Xcede Technologies, Inc. Joint Venture (Details Textual) (USD $)	1 Months Ended	6 Months Ended
	Oct. 31, 2013	Mar. 31, 2015	Mar. 31, 2014
Schedule of Equity Method Investments [Line Items]
Proceeds from Convertible Debt	$1,400,000
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Long-term Debt, Gross		3,000,000
Capital Stock Financing Discount Percentage		20.00%
Common Stock Valuation		5,000,000
Equity Method Investment, Ownership Percentage		90.00%
Share-based Compensation, Total		157,000	239,000
Xcede [Member]
Schedule of Equity Method Investments [Line Items]
Share-based Compensation, Total		$14,000

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Sep. 30, 2014
Inventory Current [Line Items]
Raw Materials	$1,875,000	$1,805,000
Work-in-Process	821,000	858,000
Finished Goods	314,000	291,000
Inventory, Net, Total	$3,010,000	$2,954,000

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	6 Months Ended	12 Months Ended
	Mar. 31, 2015	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Amount	2,054,000	2,147,000
Accumulated Amortization	819,000	764,000
Net	1,235,000	1,383,000
Acquired Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	808,000	877,000
Accumulated Amortization	419,000	409,000
Net	389,000	468,000
Acquired Customer Base [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	5 years	5 years
Acquired Customer Base [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	15 years	15 years
Know How [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	15 years	15 years
Gross Amount	512,000	512,000
Accumulated Amortization	230,000	213,000
Net	282,000	299,000
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	310,000	339,000
Accumulated Amortization	0	0
Net	310,000	339,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	20 years	20 years
Gross Amount	164,000	159,000
Accumulated Amortization	0	0
Net	164,000	159,000
Biomedical Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (years)	5 years	5 years
Gross Amount	260,000	260,000
Accumulated Amortization	170,000	142,000
Net	90,000	118,000

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Mar. 31, 2015
Finite-Lived Intangible Assets [Line Items]
2015 (6 months)	$95,000
2016	182,000
2017	122,000
2018	122,000
2019	122,000
Thereafter	282,000
Total	925,000
Acquired Customer Base [Member]
Finite-Lived Intangible Assets [Line Items]
2015 (6 months)	40,000
2016	80,000
2017	80,000
2018	80,000
2019	80,000
Thereafter	29,000
Total	389,000
Know How [Member]
Finite-Lived Intangible Assets [Line Items]
2015 (6 months)	17,000
2016	34,000
2017	34,000
2018	34,000
2019	34,000
Thereafter	129,000
Total	282,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2015 (6 months)	8,000
2016	8,000
2017	8,000
2018	8,000
2019	8,000
Thereafter	124,000
Total	164,000
Biomedical Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
2015 (6 months)	30,000
2016	60,000
2017	0
2018	0
2019	0
Thereafter	0
Total	$90,000

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$42,000	$44,000	$85,000	$89,000

Earnings_Loss_Per_Common_Share2

Earnings (Loss) Per Common Share (Details)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Weighted average shares outstanding
Basic	16,365,688	15,102,023	16,333,295	15,061,890
Effect of dilutive securities
Dilutive Average Shares Outstanding	16,365,688	15,285,232	16,333,295	15,216,915
Employee Stock Option [Member]
Effect of dilutive securities
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	0	0	0
Restricted Stock [Member]
Effect of dilutive securities
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	183,209	0	155,025

Earnings_Loss_Per_Common_Share3

Earnings (Loss) Per Common Share (Details Textual)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Earnings Loss Per Common Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	58,212	630,532	58,212	630,532

Stock_Based_Compensation_Detai

Stock Based Compensation (Details)	6 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term in years	3 years
Risk-free interest rate	0.77%
Expected volatility	89.46%
Expected dividend yield	0.00%

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Sep. 30, 2014	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance,Options Outstanding			430,532
Outstanding and exercisable,Options Outstanding			58,212
Granted,Options Outstanding	36,232		36,232
Exercised,Options Outstanding			0
Cancelled, Options Outstanding			-408,552
Balance,Options Outstanding	58,212	430,532	58,212
Balance,Weighted Average Exercise Price per Share			$3.33
Outstanding and exercisable,Weighted Average Exercise Price per Share			$2.28
Granted,Weighted Average Exercise Price per Share			$1.82
Exercised,Weighted Average Exercise Price per Share			$0
Cancelled,Weighted Average Exercise Price per Share			$3.99
Balance,Weighted Average Exercise Price per Share	$2.28	$3.33	$2.28
Balance,Weighted Average Remain Contractual Term (in Years)		3 months 22 days	2 years 5 months 19 days
Granted,Weighted Average Remain Contractual Term (in Years)			2 years 10 months 2 days
Outstanding and exercisable,Weighted Average Remain Contractual Term (in Years)			2 years 5 months 19 days

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details 2) (USD $)	6 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Nonvested, Beginning Balance	54,000
Shares, Granted	0
Shares, Vested	-27,000
Shares, Cancelled	0
Shares, Nonvested, Ending Balance	27,000
Weighted-Average Grant-Date Fair Value, Nonvested, Beginning Balance	$1.04
Weighted-Average Grant-Date Fair Value, Granted	$0
Weighted-Average Grant-Date Fair Value, Vested	$1.04
Weighted-Average Grant-Date Fair Value, Cancelled	$0
Weighted-Average Grant-Date Fair Value, Nonvested, Ending Balance	$1.04

Stock_Based_Compensation_Detai3

Stock Based Compensation (Details 3) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	$92,000	$120,000	$157,000	$239,000
Stock Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	80,000	51,000	137,000	101,000
Resticted Stock Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	7,000	68,000	14,000	137,000
Option Grants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	4,000	0	4,000	0
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Compensation Expense	$1,000	$1,000	$2,000	$1,000

Stock_Based_Compensation_Detai4

Stock Based Compensation (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Class of Stock [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$60,000		$60,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Allocated Share-based Compensation Expense	92,000	120,000	157,000	239,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	36,232		36,232
Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share	$1.82
Allocated Share-based Compensation Expense	$25,000

Segment_Customer_and_Geographi2

Segment, Customer and Geographical Reporting (Details) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$9,895,000	$10,407,000	$19,506,000	$21,118,000
Gross Profit	3,760,000	4,359,000	7,352,000	8,809,000
Gain on sale of assets	0	0	185,000	1,187,000
Operating Income (Loss)	14,000	467,000	-415,000	2,081,000
Depreciation and Amortization			586,000	535,000
Capital expenditures			456,000	539,000
Intangibles, Net	1,235,000		1,235,000		1,383,000
Goodwill	6,096,000		6,096,000		6,247,000
Total Assets	25,619,000		25,619,000		26,377,000
Results Of Operations For Three Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue	9,895,000	10,407,000
Gross Profit	3,760,000	4,359,000
GM %	38.00%	41.90%
SG&A	3,746,000	3,892,000
Gain on sale of assets	0	0
Operating Income (Loss)	14,000	467,000
Depreciation and Amortization	293,000	268,000
Capital expenditures	212,000	409,000
Intangibles, Net	1,235,000	1,322,000	1,235,000	1,322,000
Goodwill	6,096,000	6,272,000	6,096,000	6,272,000
Total Assets	25,619,000	24,833,000	25,619,000	24,833,000
Results Of Operations For Six Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue			19,506,000	21,118,000
Gross Profit			7,352,000	8,809,000
GM %			37.70%	41.70%
SG&A			7,952,000	7,915,000
Gain on sale of assets			-185,000	-1,187,000
Operating Income (Loss)			-415,000	2,081,000
Depreciation and Amortization			586,000	535,000
Capital expenditures			456,000	539,000
Intangibles, Net	1,235,000	1,322,000	1,235,000	1,322,000
Goodwill	6,096,000	6,272,000	6,096,000	6,272,000
Total Assets	25,619,000	24,833,000	25,619,000	24,833,000
Contract Research [Member] | Results Of Operations For Three Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue	4,675,000	5,614,000
Gross Profit	1,952,000	2,442,000
GM %	41.80%	43.50%
SG&A	1,896,000	2,200,000
Gain on sale of assets	0	0
Operating Income (Loss)	56,000	242,000
Depreciation and Amortization	74,000	70,000
Capital expenditures	4,000	12,000
Intangibles, Net	282,000	316,000	282,000	316,000
Goodwill	4,939,000	4,939,000	4,939,000	4,939,000
Total Assets	8,887,000	10,230,000	8,887,000	10,230,000
Contract Research [Member] | Results Of Operations For Six Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue			9,338,000	11,454,000
Gross Profit			4,050,000	4,971,000
GM %			43.40%	43.40%
SG&A			3,778,000	4,381,000
Gain on sale of assets			0	0
Operating Income (Loss)			272,000	590,000
Depreciation and Amortization			148,000	139,000
Capital expenditures			4,000	12,000
Intangibles, Net	282,000	316,000	282,000	316,000
Goodwill	4,939,000	4,939,000	4,939,000	4,939,000
Total Assets	8,887,000	10,230,000	8,887,000	10,230,000
Optics [Member] | Results Of Operations For Three Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue	5,220,000	4,789,000
Gross Profit	1,808,000	1,919,000
GM %	34.60%	40.10%
SG&A	1,580,000	1,397,000
Gain on sale of assets	0	0
Operating Income (Loss)	228,000	522,000
Depreciation and Amortization	204,000	183,000
Capital expenditures	152,000	397,000
Intangibles, Net	699,000	858,000	699,000	858,000
Goodwill	1,157,000	1,333,000	1,157,000	1,333,000
Total Assets	15,800,000	13,816,000	15,800,000	13,816,000
Optics [Member] | Results Of Operations For Six Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue			10,168,000	8,887,000
Gross Profit			3,302,000	3,517,000
GM %			32.50%	39.60%
SG&A			3,670,000	2,596,000
Gain on sale of assets			-185,000	0
Operating Income (Loss)			-183,000	921,000
Depreciation and Amortization			408,000	362,000
Capital expenditures			396,000	527,000
Intangibles, Net	699,000	858,000	699,000	858,000
Goodwill	1,157,000	1,333,000	1,157,000	1,333,000
Total Assets	15,800,000	13,816,000	15,800,000	13,816,000
Instruments [Member] | Results Of Operations For Three Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue	0	0
Gross Profit	0	-6,000
GM %	0.00%	0.00%
SG&A	0	70,000
Gain on sale of assets	0	0
Operating Income (Loss)	0	-76,000
Depreciation and Amortization	0	0
Capital expenditures	0	0
Intangibles, Net	0	0	0	0
Goodwill	0	0	0	0
Total Assets	238,000	455,000	238,000	455,000
Instruments [Member] | Results Of Operations For Six Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue			0	773,000
Gross Profit			0	317,000
GM %			0.00%	41.00%
SG&A			0	539,000
Gain on sale of assets			0	-1,187,000
Operating Income (Loss)			0	965,000
Depreciation and Amortization			0	2,000
Capital expenditures			0	0
Intangibles, Net	0	0	0	0
Goodwill	0	0	0	0
Total Assets	238,000	455,000	238,000	455,000
Biomedical [Member] | Results Of Operations For Three Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue	0	4,000
Gross Profit	0	4,000
GM %	0.00%	100.00%
SG&A	270,000	225,000
Gain on sale of assets	0	0
Operating Income (Loss)	-270,000	-221,000
Depreciation and Amortization	15,000	15,000
Capital expenditures	56,000	0
Intangibles, Net	254,000	148,000	254,000	148,000
Goodwill	0	0	0	0
Total Assets	694,000	332,000	694,000	332,000
Biomedical [Member] | Results Of Operations For Six Months Ended Period [Member]
Segment Reporting Information [Line Items]
Revenue			0	4,000
Gross Profit			0	4,000
GM %			0.00%	100.00%
SG&A			504,000	399,000
Gain on sale of assets			0	0
Operating Income (Loss)			-504,000	-395,000
Depreciation and Amortization			30,000	32,000
Capital expenditures			56,000	0
Intangibles, Net	254,000	148,000	254,000	148,000
Goodwill	0	0	0	0
Total Assets	$694,000	$332,000	$694,000	$332,000

Segment_Customer_and_Geographi3

Segment, Customer and Geographical Reporting (Details 1) (USD $)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$9,895,000	$10,407,000	$19,506,000	$21,118,000
% of Total	100.00%	100.00%	100.00%	100.00%
United State [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	7,982,000	8,622,000	15,664,000	17,529,000
% of Total	81.00%	83.00%	80.00%	83.00%
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	1,124,000	845,000	2,008,000	1,675,000
% of Total	11.00%	8.00%	10.00%	8.00%
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$789,000	$940,000	$1,834,000	$1,914,000
% of Total	8.00%	9.00%	10.00%	9.00%

Segment_Customer_and_Geographi4

Segment, Customer and Geographical Reporting (Details Textual) (Sales Revenue, Segment [Member])	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	69.00%	69.00%	70.00%	67.00%
Customer Two [Member] | US Government [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage		10.00%		10.00%
Four Customers [Member] | US Government [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	10.00%		10.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Income Tax [Line Items]
Effective Income Tax Rate Reconciliation, Percent	15.84%	1.80%	3.29%	2.40%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%

Settlement_of_Pension_Liabilit1

Settlement of Pension Liability (Details Textual) (USD $)	1 Months Ended
	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefits Paid	$688,000
Defined Benefit Plan, Settlements, Benefit Obligation	$332,000